Obesity Drugs Panel To Mull Whether Products Without CV Signal Need Outcomes Trial

The Endocrinologic and Metabolic Drugs Advisory Committee also will evaluate methods for collecting cardiovascular risk information for obesity drugs with a CV safety signal, as FDA seeks input on when and how sponsors should evaluate their products.